ESC HF 2021 The treatment effect of beta-blockers on all-cause mortality in HFpEF patients was heterogenous across clusters of HFpEF, with a significant reduction in the young cluster and the AF-hypertension cluster.
ESC HF 2021 Dapagliflozin improved HF symptoms (measured by KCCQ-TSS) in HFrEF compared to placebo, but did not improve physical limitations (measured by KCCQ-PLS) or 6 minute walk distance. No significant improvements with dapagliflozin in any of these outcomes were seen in HFpEF.
ESC HF 2021 This analysis of the VICTORIA trial showed that the beneficial effects of vericiguat were unaffected by AF status at baseline.
ESC HF 2021 This subanalysis of the GALACTIC-HF trial showed that omecamtiv mecarbil treatment was less effective in HFrEF patients with baseline AF or atrial flutter (AFL), and this was prominent in digoxin treated patients with AF/AFL.
ESC HF 2021 The IRON-CRT trial showed that ferric carboxymaltose improved cardiac function as measured by LVEF, LVESV, and the force-frequency relationship in patients with HFrEF and iron deficiency.
ESC HF 2021 A subanalysis of FIDELIO-DKD showed that finerenone lowered CV and kidney outcomes compared to placebo in patients with T2DM and CKD irrespective of pre-existing HF status.
ESC HF 2021 In a nation-wide HF registry, screening for iron deficiency was performed in only 27% of patients. 19% Of patients with iron deficiency received treatment with ferric carboxymaltose.
ESC HF 2021 Use of empagliflozin was associated with reduced risk of CV and renal events, and all-cause mortality compared to use of DPP-4i in T2DM patients in a real world setting.
ESC HF 2021 Key messages of the 2021 ESC/HFA Guidelines for Heart Failure include a simplified treatment algorithm for HFrEF based on early administration of 4 classes of drugs, including SGLT2i, and tailored-treatment approaches based on phenotypes.